COVID-19
The data may show the need for one, but vaccine and immunologists are pushing back against Pfizer and BioNTech’s contention that one is necessary now.
Approximately 100 preliminary reports of GBS have been identified out of 12.8 million doses of the J&J vaccine in the U.S., according to the Centers for Disease Control and Prevention.
HHS issued their announcement, saying, “Americans who have been fully vaccinated do not need a booster shot at this time.”
Morgan had determined that adding one dose of the Moderna or Pfizer-BioNTech mRNA vaccine to one of Oxford-AstraZeneca’s viral vector technology would equal stronger immunity.
Last week presented a fair number of clinical trial news. Read on for more information.
The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.
Sinovac’s CoronaVac was the first COVID-19 vaccine approved in China for emergency use back in June 2020.
Ivermectin has become a contentious issue as to whether it effectively prevents and treats COVID-19. Several studies suggest it is effective, while others have indicated it is not.
The vaccine demonstrated efficacy in mild, moderate, and severe COVID-19 of 77.8% with efficacy against severe disease of 93.4%.
The WHO is calling for manufacturers to cut prices and increase the availability of supplies to low- and middle-income nations to parts of the world where COVID-19 continues to surge.
PRESS RELEASES